nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapagliflozin—UGT1A9—Mycophenolic acid—psoriasis	0.101	0.13	CbGbCtD
Dapagliflozin—UGT2B7—Mycophenolic acid—psoriasis	0.0956	0.123	CbGbCtD
Dapagliflozin—CYP1A1—Clobetasol propionate—psoriasis	0.0777	0.0996	CbGbCtD
Dapagliflozin—UGT1A9—Mycophenolate mofetil—psoriasis	0.0564	0.0724	CbGbCtD
Dapagliflozin—UGT2B7—Mycophenolate mofetil—psoriasis	0.0534	0.0685	CbGbCtD
Dapagliflozin—CYP2A6—Methoxsalen—psoriasis	0.0478	0.0612	CbGbCtD
Dapagliflozin—CYP1A1—Methoxsalen—psoriasis	0.0408	0.0523	CbGbCtD
Dapagliflozin—CYP1A2—Clobetasol propionate—psoriasis	0.0347	0.0445	CbGbCtD
Dapagliflozin—CYP1A1—Cholecalciferol—psoriasis	0.027	0.0347	CbGbCtD
Dapagliflozin—CYP2A6—Prednisolone—psoriasis	0.0232	0.0298	CbGbCtD
Dapagliflozin—CYP1A2—Methoxsalen—psoriasis	0.0182	0.0234	CbGbCtD
Dapagliflozin—CYP2D6—Hydroxyurea—psoriasis	0.0164	0.0211	CbGbCtD
Dapagliflozin—CYP2A6—Dexamethasone—psoriasis	0.0137	0.0175	CbGbCtD
Dapagliflozin—CYP3A4—Calcitriol—psoriasis	0.0123	0.0157	CbGbCtD
Dapagliflozin—CYP1A1—Dexamethasone—psoriasis	0.0117	0.015	CbGbCtD
Dapagliflozin—CYP2C9—Cholecalciferol—psoriasis	0.0109	0.0139	CbGbCtD
Dapagliflozin—CYP2D6—Cholecalciferol—psoriasis	0.00995	0.0128	CbGbCtD
Dapagliflozin—CYP3A4—Methoxsalen—psoriasis	0.00955	0.0122	CbGbCtD
Dapagliflozin—ABCB1—Mycophenolate mofetil—psoriasis	0.00916	0.0117	CbGbCtD
Dapagliflozin—ABCB1—Betamethasone—psoriasis	0.00785	0.0101	CbGbCtD
Dapagliflozin—ABCB1—Prednisolone—psoriasis	0.00775	0.00994	CbGbCtD
Dapagliflozin—ABCB1—Hydrocortisone—psoriasis	0.00735	0.00942	CbGbCtD
Dapagliflozin—ABCB1—Prednisone—psoriasis	0.00732	0.00938	CbGbCtD
Dapagliflozin—CYP2C9—Cyclosporine—psoriasis	0.00715	0.00917	CbGbCtD
Dapagliflozin—ABCB1—Cyclosporine—psoriasis	0.00694	0.00889	CbGbCtD
Dapagliflozin—CYP2D6—Cyclosporine—psoriasis	0.00654	0.00838	CbGbCtD
Dapagliflozin—CYP3A4—Cholecalciferol—psoriasis	0.00633	0.00811	CbGbCtD
Dapagliflozin—CYP3A4—Mycophenolate mofetil—psoriasis	0.00549	0.00703	CbGbCtD
Dapagliflozin—CYP3A4—Triamcinolone—psoriasis	0.00549	0.00703	CbGbCtD
Dapagliflozin—CYP2C9—Dexamethasone—psoriasis	0.00471	0.00604	CbGbCtD
Dapagliflozin—CYP3A4—Betamethasone—psoriasis	0.00471	0.00603	CbGbCtD
Dapagliflozin—CYP3A4—Prednisolone—psoriasis	0.00464	0.00595	CbGbCtD
Dapagliflozin—ABCB1—Dexamethasone—psoriasis	0.00457	0.00586	CbGbCtD
Dapagliflozin—CYP3A4—Hydrocortisone—psoriasis	0.0044	0.00564	CbGbCtD
Dapagliflozin—CYP3A4—Prednisone—psoriasis	0.00439	0.00562	CbGbCtD
Dapagliflozin—CYP2D6—Dexamethasone—psoriasis	0.00431	0.00552	CbGbCtD
Dapagliflozin—CYP3A4—Cyclosporine—psoriasis	0.00416	0.00533	CbGbCtD
Dapagliflozin—ABCB1—Methotrexate—psoriasis	0.00367	0.00471	CbGbCtD
Dapagliflozin—CYP3A4—Dexamethasone—psoriasis	0.00274	0.00351	CbGbCtD
Dapagliflozin—SLC5A1—NRF2 pathway—TGFA—psoriasis	0.00066	0.012	CbGpPWpGaD
Dapagliflozin—SLC5A2—NRF2 pathway—TGFA—psoriasis	0.00066	0.012	CbGpPWpGaD
Dapagliflozin—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000607	0.0111	CbGpPWpGaD
Dapagliflozin—CYP2A6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000599	0.0109	CbGpPWpGaD
Dapagliflozin—SLC5A4—SLC-mediated transmembrane transport—CP—psoriasis	0.000576	0.0105	CbGpPWpGaD
Dapagliflozin—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000536	0.00977	CbGpPWpGaD
Dapagliflozin—CYP2A6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000492	0.00897	CbGpPWpGaD
Dapagliflozin—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000452	0.00824	CbGpPWpGaD
Dapagliflozin—CYP1A1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000446	0.00813	CbGpPWpGaD
Dapagliflozin—SLC5A1—SLC-mediated transmembrane transport—CP—psoriasis	0.000436	0.00795	CbGpPWpGaD
Dapagliflozin—SLC5A2—SLC-mediated transmembrane transport—CP—psoriasis	0.000436	0.00795	CbGpPWpGaD
Dapagliflozin—UGT2B7—Biological oxidations—CYP2S1—psoriasis	0.000417	0.0076	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metapathway biotransformation—CYP2S1—psoriasis	0.000411	0.0075	CbGpPWpGaD
Dapagliflozin—SLC5A11—Transmembrane transport of small molecules—CP—psoriasis	0.000401	0.00731	CbGpPWpGaD
Dapagliflozin—SLC5A11—Transmembrane transport of small molecules—CARM1—psoriasis	0.000383	0.00697	CbGpPWpGaD
Dapagliflozin—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	0.00038	0.00693	CbGpPWpGaD
Dapagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000378	0.00689	CbGpPWpGaD
Dapagliflozin—CYP1A1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000366	0.00668	CbGpPWpGaD
Dapagliflozin—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00034	0.0062	CbGpPWpGaD
Dapagliflozin—UGT1A9—Biological oxidations—CYP2S1—psoriasis	0.000339	0.00618	CbGpPWpGaD
Dapagliflozin—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000337	0.00615	CbGpPWpGaD
Dapagliflozin—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000336	0.00612	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metapathway biotransformation—CYP2S1—psoriasis	0.000334	0.00609	CbGpPWpGaD
Dapagliflozin—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000333	0.00607	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—NDUFA5—psoriasis	0.000315	0.00574	CbGpPWpGaD
Dapagliflozin—SLC5A4—Transmembrane transport of small molecules—CP—psoriasis	0.000293	0.00533	CbGpPWpGaD
Dapagliflozin—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000289	0.00526	CbGpPWpGaD
Dapagliflozin—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000288	0.00526	CbGpPWpGaD
Dapagliflozin—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000284	0.00519	CbGpPWpGaD
Dapagliflozin—SLC5A4—Transmembrane transport of small molecules—CARM1—psoriasis	0.000279	0.00509	CbGpPWpGaD
Dapagliflozin—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000276	0.00503	CbGpPWpGaD
Dapagliflozin—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000273	0.00499	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—CYP2S1—psoriasis	0.000268	0.00488	CbGpPWpGaD
Dapagliflozin—CYP2A6—Biological oxidations—CYP2S1—psoriasis	0.000261	0.00476	CbGpPWpGaD
Dapagliflozin—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	0.000252	0.00459	CbGpPWpGaD
Dapagliflozin—Renal failure—Mycophenolate mofetil—psoriasis	0.000247	0.0015	CcSEcCtD
Dapagliflozin—Myocardial infarction—Mycophenolate mofetil—psoriasis	0.000247	0.00149	CcSEcCtD
Dapagliflozin—Rash—Methoxsalen—psoriasis	0.000246	0.00149	CcSEcCtD
Dapagliflozin—Dermatitis—Methoxsalen—psoriasis	0.000246	0.00149	CcSEcCtD
Dapagliflozin—Urticaria—Acitretin—psoriasis	0.000246	0.00149	CcSEcCtD
Dapagliflozin—Urinary tract infection—Mycophenolate mofetil—psoriasis	0.000245	0.00148	CcSEcCtD
Dapagliflozin—Body temperature increased—Acitretin—psoriasis	0.000245	0.00148	CcSEcCtD
Dapagliflozin—Headache—Methoxsalen—psoriasis	0.000244	0.00148	CcSEcCtD
Dapagliflozin—Body temperature increased—Fluocinolone Acetonide—psoriasis	0.000244	0.00148	CcSEcCtD
Dapagliflozin—Oedema—Hydroxyurea—psoriasis	0.000243	0.00147	CcSEcCtD
Dapagliflozin—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	0.000242	0.00442	CbGpPWpGaD
Dapagliflozin—Influenza—Triamcinolone—psoriasis	0.000242	0.00147	CcSEcCtD
Dapagliflozin—Infection—Hydroxyurea—psoriasis	0.000241	0.00146	CcSEcCtD
Dapagliflozin—Back pain—Mycophenolic acid—psoriasis	0.000241	0.00146	CcSEcCtD
Dapagliflozin—Vaginal infection—Methotrexate—psoriasis	0.000241	0.00146	CcSEcCtD
Dapagliflozin—SLC5A1—Metabolism—NDUFA5—psoriasis	0.000239	0.00435	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—NDUFA5—psoriasis	0.000239	0.00435	CbGpPWpGaD
Dapagliflozin—UGT1A9—PPARA activates gene expression—CARM1—psoriasis	0.000237	0.00432	CbGpPWpGaD
Dapagliflozin—CYP1A1—Oxidative Stress—CAT—psoriasis	0.000236	0.00431	CbGpPWpGaD
Dapagliflozin—Skin disorder—Hydroxyurea—psoriasis	0.000236	0.00143	CcSEcCtD
Dapagliflozin—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000234	0.00426	CbGpPWpGaD
Dapagliflozin—UGT2B7—NRF2 pathway—TGFA—psoriasis	0.000232	0.00423	CbGpPWpGaD
Dapagliflozin—Nausea—Methoxsalen—psoriasis	0.000232	0.0014	CcSEcCtD
Dapagliflozin—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.000232	0.00422	CbGpPWpGaD
Dapagliflozin—Acute coronary syndrome—Prednisolone—psoriasis	0.000231	0.0014	CcSEcCtD
Dapagliflozin—Urine output increased—Methotrexate—psoriasis	0.00023	0.0014	CcSEcCtD
Dapagliflozin—Neoplasm—Methotrexate—psoriasis	0.00023	0.0014	CcSEcCtD
Dapagliflozin—Myocardial infarction—Prednisolone—psoriasis	0.00023	0.00139	CcSEcCtD
Dapagliflozin—Infestation—Hydrocortisone—psoriasis	0.000229	0.00139	CcSEcCtD
Dapagliflozin—Infestation NOS—Hydrocortisone—psoriasis	0.000229	0.00139	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Cyclosporine—psoriasis	0.000229	0.00139	CcSEcCtD
Dapagliflozin—Hypersensitivity—Acitretin—psoriasis	0.000228	0.00138	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Cyclosporine—psoriasis	0.000228	0.00138	CcSEcCtD
Dapagliflozin—Hypersensitivity—Fluocinolone Acetonide—psoriasis	0.000227	0.00138	CcSEcCtD
Dapagliflozin—Urethral disorder—Cyclosporine—psoriasis	0.000227	0.00138	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Hydrocortisone—psoriasis	0.000226	0.00137	CcSEcCtD
Dapagliflozin—Myocardial infarction—Hydrocortisone—psoriasis	0.000225	0.00136	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Mycophenolate mofetil—psoriasis	0.000223	0.00135	CcSEcCtD
Dapagliflozin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000222	0.00406	CbGpPWpGaD
Dapagliflozin—Connective tissue disorder—Mycophenolate mofetil—psoriasis	0.000222	0.00135	CcSEcCtD
Dapagliflozin—SLC5A1—Transmembrane transport of small molecules—CP—psoriasis	0.000222	0.00404	CbGpPWpGaD
Dapagliflozin—SLC5A2—Transmembrane transport of small molecules—CP—psoriasis	0.000222	0.00404	CbGpPWpGaD
Dapagliflozin—CYP1A1—Estrogen Receptor Pathway—JUN—psoriasis	0.000222	0.00404	CbGpPWpGaD
Dapagliflozin—Urethral disorder—Mycophenolate mofetil—psoriasis	0.000222	0.00134	CcSEcCtD
Dapagliflozin—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	0.00022	0.00401	CbGpPWpGaD
Dapagliflozin—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00022	0.004	CbGpPWpGaD
Dapagliflozin—Rash—Calcitriol—psoriasis	0.000219	0.00133	CcSEcCtD
Dapagliflozin—Dermatitis—Calcitriol—psoriasis	0.000219	0.00133	CcSEcCtD
Dapagliflozin—Headache—Calcitriol—psoriasis	0.000218	0.00132	CcSEcCtD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000217	0.00395	CbGpPWpGaD
Dapagliflozin—Hypertension—Mycophenolic acid—psoriasis	0.000215	0.0013	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Triamcinolone—psoriasis	0.000213	0.00129	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Methotrexate—psoriasis	0.000213	0.00129	CcSEcCtD
Dapagliflozin—Myocardial infarction—Triamcinolone—psoriasis	0.000212	0.00128	CcSEcCtD
Dapagliflozin—SLC5A1—Transmembrane transport of small molecules—CARM1—psoriasis	0.000211	0.00386	CbGpPWpGaD
Dapagliflozin—SLC5A2—Transmembrane transport of small molecules—CARM1—psoriasis	0.000211	0.00386	CbGpPWpGaD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—psoriasis	0.000211	0.00128	CcSEcCtD
Dapagliflozin—Polyuria—Methotrexate—psoriasis	0.000211	0.00128	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Hydroxyurea—psoriasis	0.00021	0.00127	CcSEcCtD
Dapagliflozin—Discomfort—Mycophenolic acid—psoriasis	0.00021	0.00127	CcSEcCtD
Dapagliflozin—Constipation—Hydroxyurea—psoriasis	0.000208	0.00126	CcSEcCtD
Dapagliflozin—Nausea—Calcitriol—psoriasis	0.000207	0.00125	CcSEcCtD
Dapagliflozin—Dizziness—Acitretin—psoriasis	0.000205	0.00124	CcSEcCtD
Dapagliflozin—Dizziness—Fluocinolone Acetonide—psoriasis	0.000204	0.00124	CcSEcCtD
Dapagliflozin—Oedema—Mycophenolic acid—psoriasis	0.000203	0.00123	CcSEcCtD
Dapagliflozin—SLC5A2—Metabolism—CYP2S1—psoriasis	0.000203	0.0037	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—CYP2S1—psoriasis	0.000203	0.0037	CbGpPWpGaD
Dapagliflozin—Connective tissue disorder—Hydrocortisone—psoriasis	0.000202	0.00123	CcSEcCtD
Dapagliflozin—Infection—Mycophenolic acid—psoriasis	0.000202	0.00122	CcSEcCtD
Dapagliflozin—Malnutrition—Cyclosporine—psoriasis	0.000202	0.00122	CcSEcCtD
Dapagliflozin—Skin disorder—Mycophenolic acid—psoriasis	0.000198	0.0012	CcSEcCtD
Dapagliflozin—Malnutrition—Mycophenolate mofetil—psoriasis	0.000197	0.00119	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Mycophenolic acid—psoriasis	0.000197	0.00119	CcSEcCtD
Dapagliflozin—Rash—Acitretin—psoriasis	0.000195	0.00118	CcSEcCtD
Dapagliflozin—Dermatitis—Acitretin—psoriasis	0.000195	0.00118	CcSEcCtD
Dapagliflozin—CYP1A1—Biological oxidations—CYP2S1—psoriasis	0.000195	0.00355	CbGpPWpGaD
Dapagliflozin—Rash—Fluocinolone Acetonide—psoriasis	0.000195	0.00118	CcSEcCtD
Dapagliflozin—Dermatitis—Fluocinolone Acetonide—psoriasis	0.000194	0.00118	CcSEcCtD
Dapagliflozin—Headache—Acitretin—psoriasis	0.000194	0.00117	CcSEcCtD
Dapagliflozin—Headache—Fluocinolone Acetonide—psoriasis	0.000193	0.00117	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Betamethasone—psoriasis	0.000193	0.00117	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Dexamethasone—psoriasis	0.000193	0.00117	CcSEcCtD
Dapagliflozin—Myocardial infarction—Betamethasone—psoriasis	0.000192	0.00116	CcSEcCtD
Dapagliflozin—Myocardial infarction—Dexamethasone—psoriasis	0.000192	0.00116	CcSEcCtD
Dapagliflozin—Body temperature increased—Hydroxyurea—psoriasis	0.000192	0.00116	CcSEcCtD
Dapagliflozin—CYP1A1—Metapathway biotransformation—CYP2S1—psoriasis	0.000192	0.0035	CbGpPWpGaD
Dapagliflozin—CYP1A1—Estrogen Receptor Pathway—STAT3—psoriasis	0.000192	0.00349	CbGpPWpGaD
Dapagliflozin—Back pain—Mycophenolate mofetil—psoriasis	0.00019	0.00115	CcSEcCtD
Dapagliflozin—Hypotension—Mycophenolic acid—psoriasis	0.00019	0.00115	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Methotrexate—psoriasis	0.000189	0.00114	CcSEcCtD
Dapagliflozin—CYP1A1—Melatonin metabolism and effects—APOE—psoriasis	0.000189	0.00344	CbGpPWpGaD
Dapagliflozin—UGT1A9—NRF2 pathway—TGFA—psoriasis	0.000189	0.00344	CbGpPWpGaD
Dapagliflozin—Angioedema—Cyclosporine—psoriasis	0.000184	0.00112	CcSEcCtD
Dapagliflozin—UGT2B4—Metabolism—NDUFA5—psoriasis	0.000184	0.00336	CbGpPWpGaD
Dapagliflozin—Nausea—Acitretin—psoriasis	0.000184	0.00111	CcSEcCtD
Dapagliflozin—Nausea—Fluocinolone Acetonide—psoriasis	0.000183	0.00111	CcSEcCtD
Dapagliflozin—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00018	0.00329	CbGpPWpGaD
Dapagliflozin—Angioedema—Mycophenolate mofetil—psoriasis	0.00018	0.00109	CcSEcCtD
Dapagliflozin—Malnutrition—Hydrocortisone—psoriasis	0.000179	0.00109	CcSEcCtD
Dapagliflozin—Hypersensitivity—Hydroxyurea—psoriasis	0.000179	0.00108	CcSEcCtD
Dapagliflozin—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000178	0.00324	CbGpPWpGaD
Dapagliflozin—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000176	0.00106	CcSEcCtD
Dapagliflozin—Hypertension—Cyclosporine—psoriasis	0.000174	0.00105	CcSEcCtD
Dapagliflozin—Constipation—Mycophenolic acid—psoriasis	0.000174	0.00105	CcSEcCtD
Dapagliflozin—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.000171	0.00312	CbGpPWpGaD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	0.000171	0.00103	CcSEcCtD
Dapagliflozin—Hypertension—Mycophenolate mofetil—psoriasis	0.00017	0.00103	CcSEcCtD
Dapagliflozin—Discomfort—Cyclosporine—psoriasis	0.00017	0.00103	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Prednisone—psoriasis	0.000168	0.00102	CcSEcCtD
Dapagliflozin—CYP1A1—Tryptophan metabolism—CAT—psoriasis	0.000168	0.00306	CbGpPWpGaD
Dapagliflozin—Angioedema—Prednisolone—psoriasis	0.000168	0.00102	CcSEcCtD
Dapagliflozin—Myocardial infarction—Prednisone—psoriasis	0.000167	0.00101	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.000166	0.00101	CcSEcCtD
Dapagliflozin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000166	0.00302	CbGpPWpGaD
Dapagliflozin—Discomfort—Mycophenolate mofetil—psoriasis	0.000165	0.001	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Cyclosporine—psoriasis	0.000165	0.000997	CcSEcCtD
Dapagliflozin—Oedema—Cyclosporine—psoriasis	0.000165	0.000997	CcSEcCtD
Dapagliflozin—Angioedema—Hydrocortisone—psoriasis	0.000164	0.000992	CcSEcCtD
Dapagliflozin—Infection—Cyclosporine—psoriasis	0.000164	0.00099	CcSEcCtD
Dapagliflozin—Back pain—Triamcinolone—psoriasis	0.000163	0.000989	CcSEcCtD
Dapagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.000162	0.00296	CbGpPWpGaD
Dapagliflozin—Body temperature increased—Mycophenolic acid—psoriasis	0.000161	0.000974	CcSEcCtD
Dapagliflozin—Dizziness—Hydroxyurea—psoriasis	0.000161	0.000973	CcSEcCtD
Dapagliflozin—Oedema—Mycophenolate mofetil—psoriasis	0.000161	0.000973	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Mycophenolate mofetil—psoriasis	0.000161	0.000973	CcSEcCtD
Dapagliflozin—Skin disorder—Cyclosporine—psoriasis	0.00016	0.000968	CcSEcCtD
Dapagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.00016	0.00291	CbGpPWpGaD
Dapagliflozin—Infection—Mycophenolate mofetil—psoriasis	0.00016	0.000966	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Cyclosporine—psoriasis	0.000159	0.000964	CcSEcCtD
Dapagliflozin—Hypertension—Prednisolone—psoriasis	0.000158	0.00096	CcSEcCtD
Dapagliflozin—UGT2B4—Metabolism—CYP2S1—psoriasis	0.000157	0.00286	CbGpPWpGaD
Dapagliflozin—Skin disorder—Mycophenolate mofetil—psoriasis	0.000156	0.000945	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Mycophenolate mofetil—psoriasis	0.000155	0.00094	CcSEcCtD
Dapagliflozin—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000155	0.00282	CbGpPWpGaD
Dapagliflozin—Hypertension—Hydrocortisone—psoriasis	0.000155	0.000937	CcSEcCtD
Dapagliflozin—Discomfort—Prednisolone—psoriasis	0.000154	0.000935	CcSEcCtD
Dapagliflozin—Angioedema—Triamcinolone—psoriasis	0.000154	0.000934	CcSEcCtD
Dapagliflozin—Rash—Hydroxyurea—psoriasis	0.000153	0.000928	CcSEcCtD
Dapagliflozin—Dermatitis—Hydroxyurea—psoriasis	0.000153	0.000927	CcSEcCtD
Dapagliflozin—Headache—Hydroxyurea—psoriasis	0.000152	0.000922	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000152	0.000918	CcSEcCtD
Dapagliflozin—Discomfort—Hydrocortisone—psoriasis	0.000151	0.000913	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Prednisone—psoriasis	0.000151	0.000912	CcSEcCtD
Dapagliflozin—Hypotension—Mycophenolate mofetil—psoriasis	0.00015	0.000909	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Prednisolone—psoriasis	0.00015	0.000907	CcSEcCtD
Dapagliflozin—Oedema—Prednisolone—psoriasis	0.00015	0.000907	CcSEcCtD
Dapagliflozin—Dysuria—Methotrexate—psoriasis	0.00015	0.000906	CcSEcCtD
Dapagliflozin—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000147	0.00267	CbGpPWpGaD
Dapagliflozin—Oedema—Hydrocortisone—psoriasis	0.000146	0.000886	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Hydrocortisone—psoriasis	0.000146	0.000886	CcSEcCtD
Dapagliflozin—Hypertension—Triamcinolone—psoriasis	0.000146	0.000883	CcSEcCtD
Dapagliflozin—CYP2A6—NRF2 pathway—TGFA—psoriasis	0.000145	0.00265	CbGpPWpGaD
Dapagliflozin—Infection—Hydrocortisone—psoriasis	0.000145	0.00088	CcSEcCtD
Dapagliflozin—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000145	0.00265	CbGpPWpGaD
Dapagliflozin—Hyperhidrosis—Prednisolone—psoriasis	0.000145	0.000877	CcSEcCtD
Dapagliflozin—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000145	0.00263	CbGpPWpGaD
Dapagliflozin—Nausea—Hydroxyurea—psoriasis	0.000144	0.000874	CcSEcCtD
Dapagliflozin—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000143	0.00261	CbGpPWpGaD
Dapagliflozin—Infestation NOS—Methotrexate—psoriasis	0.000143	0.000864	CcSEcCtD
Dapagliflozin—Infestation—Methotrexate—psoriasis	0.000143	0.000864	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000142	0.000861	CcSEcCtD
Dapagliflozin—Skin disorder—Hydrocortisone—psoriasis	0.000142	0.000861	CcSEcCtD
Dapagliflozin—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000142	0.00259	CbGpPWpGaD
Dapagliflozin—Discomfort—Triamcinolone—psoriasis	0.000142	0.00086	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Hydrocortisone—psoriasis	0.000141	0.000857	CcSEcCtD
Dapagliflozin—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.000141	0.00258	CbGpPWpGaD
Dapagliflozin—Constipation—Cyclosporine—psoriasis	0.000141	0.000853	CcSEcCtD
Dapagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	0.00014	0.00256	CbGpPWpGaD
Dapagliflozin—Renal failure—Methotrexate—psoriasis	0.00014	0.000849	CcSEcCtD
Dapagliflozin—Angioedema—Betamethasone—psoriasis	0.00014	0.000848	CcSEcCtD
Dapagliflozin—Angioedema—Dexamethasone—psoriasis	0.00014	0.000848	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000139	0.00084	CcSEcCtD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000138	0.00252	CbGpPWpGaD
Dapagliflozin—Oedema—Triamcinolone—psoriasis	0.000138	0.000834	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Triamcinolone—psoriasis	0.000138	0.000834	CcSEcCtD
Dapagliflozin—Constipation—Mycophenolate mofetil—psoriasis	0.000137	0.000832	CcSEcCtD
Dapagliflozin—Infection—Triamcinolone—psoriasis	0.000137	0.000829	CcSEcCtD
Dapagliflozin—Hypotension—Hydrocortisone—psoriasis	0.000137	0.000828	CcSEcCtD
Dapagliflozin—CYP1A1—PPARA activates gene expression—CARM1—psoriasis	0.000136	0.00248	CbGpPWpGaD
Dapagliflozin—Dizziness—Mycophenolic acid—psoriasis	0.000135	0.000815	CcSEcCtD
Dapagliflozin—Malnutrition—Prednisone—psoriasis	0.000133	0.000808	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Triamcinolone—psoriasis	0.000133	0.000807	CcSEcCtD
Dapagliflozin—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.000133	0.00243	CbGpPWpGaD
Dapagliflozin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000132	0.00241	CbGpPWpGaD
Dapagliflozin—Hypertension—Betamethasone—psoriasis	0.000132	0.000801	CcSEcCtD
Dapagliflozin—Hypertension—Dexamethasone—psoriasis	0.000132	0.000801	CcSEcCtD
Dapagliflozin—ABCB1—Allograft Rejection—HLA-C—psoriasis	0.000132	0.00241	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—IL13—psoriasis	0.000131	0.0024	CbGpPWpGaD
Dapagliflozin—Urticaria—Cyclosporine—psoriasis	0.000131	0.000792	CcSEcCtD
Dapagliflozin—SLC5A4—Metabolism—CARM1—psoriasis	0.000131	0.00238	CbGpPWpGaD
Dapagliflozin—Body temperature increased—Cyclosporine—psoriasis	0.00013	0.000788	CcSEcCtD
Dapagliflozin—Discomfort—Betamethasone—psoriasis	0.000129	0.00078	CcSEcCtD
Dapagliflozin—Discomfort—Dexamethasone—psoriasis	0.000129	0.00078	CcSEcCtD
Dapagliflozin—Rash—Mycophenolic acid—psoriasis	0.000128	0.000777	CcSEcCtD
Dapagliflozin—Dermatitis—Mycophenolic acid—psoriasis	0.000128	0.000776	CcSEcCtD
Dapagliflozin—Urticaria—Mycophenolate mofetil—psoriasis	0.000128	0.000773	CcSEcCtD
Dapagliflozin—Headache—Mycophenolic acid—psoriasis	0.000127	0.000772	CcSEcCtD
Dapagliflozin—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000127	0.000769	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Methotrexate—psoriasis	0.000126	0.000766	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000126	0.000765	CcSEcCtD
Dapagliflozin—Urethral disorder—Methotrexate—psoriasis	0.000125	0.00076	CcSEcCtD
Dapagliflozin—Oedema—Betamethasone—psoriasis	0.000125	0.000757	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Dexamethasone—psoriasis	0.000125	0.000757	CcSEcCtD
Dapagliflozin—Oedema—Dexamethasone—psoriasis	0.000125	0.000757	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Betamethasone—psoriasis	0.000125	0.000757	CcSEcCtD
Dapagliflozin—Infection—Betamethasone—psoriasis	0.000124	0.000752	CcSEcCtD
Dapagliflozin—Infection—Dexamethasone—psoriasis	0.000124	0.000752	CcSEcCtD
Dapagliflozin—CYP1A2—Biological oxidations—CYP2S1—psoriasis	0.000124	0.00226	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	0.000122	0.00223	CbGpPWpGaD
Dapagliflozin—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	0.000122	0.00223	CbGpPWpGaD
Dapagliflozin—Angioedema—Prednisone—psoriasis	0.000122	0.000738	CcSEcCtD
Dapagliflozin—Hypersensitivity—Cyclosporine—psoriasis	0.000121	0.000735	CcSEcCtD
Dapagliflozin—ABCB1—Allograft Rejection—IL17A—psoriasis	0.000121	0.0022	CbGpPWpGaD
Dapagliflozin—Nausea—Mycophenolic acid—psoriasis	0.000121	0.000732	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Betamethasone—psoriasis	0.000121	0.000732	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Dexamethasone—psoriasis	0.000121	0.000732	CcSEcCtD
Dapagliflozin—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	0.00012	0.00219	CbGpPWpGaD
Dapagliflozin—Urticaria—Prednisolone—psoriasis	0.000119	0.000721	CcSEcCtD
Dapagliflozin—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000118	0.000717	CcSEcCtD
Dapagliflozin—Hypotension—Dexamethasone—psoriasis	0.000117	0.000707	CcSEcCtD
Dapagliflozin—Hypotension—Betamethasone—psoriasis	0.000117	0.000707	CcSEcCtD
Dapagliflozin—Urticaria—Hydrocortisone—psoriasis	0.000116	0.000704	CcSEcCtD
Dapagliflozin—Body temperature increased—Hydrocortisone—psoriasis	0.000116	0.0007	CcSEcCtD
Dapagliflozin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000116	0.00211	CbGpPWpGaD
Dapagliflozin—Hypertension—Prednisone—psoriasis	0.000115	0.000697	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000113	0.000683	CcSEcCtD
Dapagliflozin—ABCB1—Allograft Rejection—IL12B—psoriasis	0.000112	0.00205	CbGpPWpGaD
Dapagliflozin—CYP1A1—Melatonin metabolism and effects—NFKB1—psoriasis	0.000112	0.00205	CbGpPWpGaD
Dapagliflozin—Discomfort—Prednisone—psoriasis	0.000112	0.000679	CcSEcCtD
Dapagliflozin—Malnutrition—Methotrexate—psoriasis	0.000111	0.000675	CcSEcCtD
Dapagliflozin—Hypersensitivity—Prednisolone—psoriasis	0.00011	0.000668	CcSEcCtD
Dapagliflozin—ABCB1—Allograft Rejection—HLA-E—psoriasis	0.00011	0.002	CbGpPWpGaD
Dapagliflozin—Urticaria—Triamcinolone—psoriasis	0.000109	0.000663	CcSEcCtD
Dapagliflozin—CYP1A1—Oxidative Stress—NFKB1—psoriasis	0.000109	0.00199	CbGpPWpGaD
Dapagliflozin—Body temperature increased—Triamcinolone—psoriasis	0.000109	0.00066	CcSEcCtD
Dapagliflozin—Dizziness—Cyclosporine—psoriasis	0.000109	0.000659	CcSEcCtD
Dapagliflozin—Oedema—Prednisone—psoriasis	0.000109	0.000659	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Prednisone—psoriasis	0.000109	0.000659	CcSEcCtD
Dapagliflozin—Infection—Prednisone—psoriasis	0.000108	0.000655	CcSEcCtD
Dapagliflozin—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000108	0.00197	CbGpPWpGaD
Dapagliflozin—Gastrointestinal disorder—Betamethasone—psoriasis	0.000108	0.000654	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000108	0.000654	CcSEcCtD
Dapagliflozin—Back pain—Methotrexate—psoriasis	0.000108	0.000653	CcSEcCtD
Dapagliflozin—Hypersensitivity—Hydrocortisone—psoriasis	0.000108	0.000653	CcSEcCtD
Dapagliflozin—CYP1A2—Tryptophan metabolism—CAT—psoriasis	0.000107	0.00195	CbGpPWpGaD
Dapagliflozin—Dizziness—Mycophenolate mofetil—psoriasis	0.000106	0.000643	CcSEcCtD
Dapagliflozin—Skin disorder—Prednisone—psoriasis	0.000106	0.00064	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Prednisone—psoriasis	0.000105	0.000637	CcSEcCtD
Dapagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	0.000105	0.00192	CbGpPWpGaD
Dapagliflozin—Rash—Cyclosporine—psoriasis	0.000104	0.000629	CcSEcCtD
Dapagliflozin—Dermatitis—Cyclosporine—psoriasis	0.000104	0.000628	CcSEcCtD
Dapagliflozin—Headache—Cyclosporine—psoriasis	0.000103	0.000625	CcSEcCtD
Dapagliflozin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000102	0.00186	CbGpPWpGaD
Dapagliflozin—Hypersensitivity—Triamcinolone—psoriasis	0.000101	0.000615	CcSEcCtD
Dapagliflozin—Rash—Mycophenolate mofetil—psoriasis	0.000101	0.000613	CcSEcCtD
Dapagliflozin—Dermatitis—Mycophenolate mofetil—psoriasis	0.000101	0.000613	CcSEcCtD
Dapagliflozin—Headache—Mycophenolate mofetil—psoriasis	0.000101	0.000609	CcSEcCtD
Dapagliflozin—Urticaria—Dexamethasone—psoriasis	9.93e-05	0.000601	CcSEcCtD
Dapagliflozin—Urticaria—Betamethasone—psoriasis	9.93e-05	0.000601	CcSEcCtD
Dapagliflozin—SLC5A2—Metabolism—CARM1—psoriasis	9.91e-05	0.00181	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—CARM1—psoriasis	9.91e-05	0.00181	CbGpPWpGaD
Dapagliflozin—Dizziness—Prednisolone—psoriasis	9.9e-05	0.0006	CcSEcCtD
Dapagliflozin—Body temperature increased—Dexamethasone—psoriasis	9.88e-05	0.000598	CcSEcCtD
Dapagliflozin—Body temperature increased—Betamethasone—psoriasis	9.88e-05	0.000598	CcSEcCtD
Dapagliflozin—UGT1A9—PPARA activates gene expression—PPARG—psoriasis	9.85e-05	0.0018	CbGpPWpGaD
Dapagliflozin—Nausea—Cyclosporine—psoriasis	9.78e-05	0.000592	CcSEcCtD
Dapagliflozin—Dizziness—Hydrocortisone—psoriasis	9.67e-05	0.000586	CcSEcCtD
Dapagliflozin—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	9.64e-05	0.00176	CbGpPWpGaD
Dapagliflozin—CYP3A4—Biological oxidations—CYP2S1—psoriasis	9.58e-05	0.00175	CbGpPWpGaD
Dapagliflozin—Nausea—Mycophenolate mofetil—psoriasis	9.54e-05	0.000578	CcSEcCtD
Dapagliflozin—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	9.45e-05	0.00172	CbGpPWpGaD
Dapagliflozin—Rash—Prednisolone—psoriasis	9.44e-05	0.000572	CcSEcCtD
Dapagliflozin—Dermatitis—Prednisolone—psoriasis	9.43e-05	0.000571	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	9.42e-05	0.000571	CcSEcCtD
Dapagliflozin—Headache—Prednisolone—psoriasis	9.38e-05	0.000568	CcSEcCtD
Dapagliflozin—Discomfort—Methotrexate—psoriasis	9.37e-05	0.000568	CcSEcCtD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	9.33e-05	0.0017	CbGpPWpGaD
Dapagliflozin—CYP2A6—Fluoropyrimidine Activity—TP53—psoriasis	9.32e-05	0.0017	CbGpPWpGaD
Dapagliflozin—Constipation—Prednisone—psoriasis	9.31e-05	0.000564	CcSEcCtD
Dapagliflozin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	9.23e-05	0.00168	CbGpPWpGaD
Dapagliflozin—Rash—Hydrocortisone—psoriasis	9.22e-05	0.000559	CcSEcCtD
Dapagliflozin—Dermatitis—Hydrocortisone—psoriasis	9.21e-05	0.000558	CcSEcCtD
Dapagliflozin—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	9.17e-05	0.00167	CbGpPWpGaD
Dapagliflozin—Headache—Hydrocortisone—psoriasis	9.16e-05	0.000555	CcSEcCtD
Dapagliflozin—Dizziness—Triamcinolone—psoriasis	9.11e-05	0.000552	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Methotrexate—psoriasis	9.1e-05	0.000551	CcSEcCtD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	9.08e-05	0.00166	CbGpPWpGaD
Dapagliflozin—Infection—Methotrexate—psoriasis	9.04e-05	0.000547	CcSEcCtD
Dapagliflozin—Nausea—Prednisolone—psoriasis	8.9e-05	0.000539	CcSEcCtD
Dapagliflozin—Skin disorder—Methotrexate—psoriasis	8.83e-05	0.000535	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Methotrexate—psoriasis	8.79e-05	0.000533	CcSEcCtD
Dapagliflozin—Nausea—Hydrocortisone—psoriasis	8.69e-05	0.000526	CcSEcCtD
Dapagliflozin—Rash—Triamcinolone—psoriasis	8.68e-05	0.000526	CcSEcCtD
Dapagliflozin—Dermatitis—Triamcinolone—psoriasis	8.68e-05	0.000526	CcSEcCtD
Dapagliflozin—Urticaria—Prednisone—psoriasis	8.65e-05	0.000524	CcSEcCtD
Dapagliflozin—Headache—Triamcinolone—psoriasis	8.63e-05	0.000523	CcSEcCtD
Dapagliflozin—Body temperature increased—Prednisone—psoriasis	8.6e-05	0.000521	CcSEcCtD
Dapagliflozin—Hypotension—Methotrexate—psoriasis	8.5e-05	0.000515	CcSEcCtD
Dapagliflozin—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	8.45e-05	0.00154	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—NDUFA5—psoriasis	8.39e-05	0.00153	CbGpPWpGaD
Dapagliflozin—CYP3A4—Tryptophan metabolism—CAT—psoriasis	8.26e-05	0.00151	CbGpPWpGaD
Dapagliflozin—Dizziness—Betamethasone—psoriasis	8.26e-05	0.000501	CcSEcCtD
Dapagliflozin—Dizziness—Dexamethasone—psoriasis	8.26e-05	0.000501	CcSEcCtD
Dapagliflozin—ABCB1—Allograft Rejection—IL10—psoriasis	8.22e-05	0.0015	CbGpPWpGaD
Dapagliflozin—Nausea—Triamcinolone—psoriasis	8.18e-05	0.000496	CcSEcCtD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	8.06e-05	0.00147	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—CAT—psoriasis	8.04e-05	0.00147	CbGpPWpGaD
Dapagliflozin—Hypersensitivity—Prednisone—psoriasis	8.02e-05	0.000486	CcSEcCtD
Dapagliflozin—ABCB1—Allograft Rejection—IL4—psoriasis	7.99e-05	0.00146	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—HLA-A—psoriasis	7.99e-05	0.00146	CbGpPWpGaD
Dapagliflozin—Rash—Betamethasone—psoriasis	7.88e-05	0.000477	CcSEcCtD
Dapagliflozin—Rash—Dexamethasone—psoriasis	7.88e-05	0.000477	CcSEcCtD
Dapagliflozin—Dermatitis—Betamethasone—psoriasis	7.87e-05	0.000477	CcSEcCtD
Dapagliflozin—Dermatitis—Dexamethasone—psoriasis	7.87e-05	0.000477	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Methotrexate—psoriasis	7.85e-05	0.000476	CcSEcCtD
Dapagliflozin—Headache—Dexamethasone—psoriasis	7.83e-05	0.000474	CcSEcCtD
Dapagliflozin—Headache—Betamethasone—psoriasis	7.83e-05	0.000474	CcSEcCtD
Dapagliflozin—ABCB1—Allograft Rejection—HLA-B—psoriasis	7.82e-05	0.00143	CbGpPWpGaD
Dapagliflozin—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	7.81e-05	0.00142	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	7.76e-05	0.00141	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—CARM1—psoriasis	7.65e-05	0.00139	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—APOE—psoriasis	7.46e-05	0.00136	CbGpPWpGaD
Dapagliflozin—Nausea—Betamethasone—psoriasis	7.42e-05	0.00045	CcSEcCtD
Dapagliflozin—Nausea—Dexamethasone—psoriasis	7.42e-05	0.00045	CcSEcCtD
Dapagliflozin—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	7.28e-05	0.00133	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—HLA-A—psoriasis	7.24e-05	0.00132	CbGpPWpGaD
Dapagliflozin—Urticaria—Methotrexate—psoriasis	7.23e-05	0.000438	CcSEcCtD
Dapagliflozin—Dizziness—Prednisone—psoriasis	7.2e-05	0.000436	CcSEcCtD
Dapagliflozin—Body temperature increased—Methotrexate—psoriasis	7.19e-05	0.000436	CcSEcCtD
Dapagliflozin—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	7.16e-05	0.0013	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—CYP2S1—psoriasis	7.13e-05	0.0013	CbGpPWpGaD
Dapagliflozin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.12e-05	0.0013	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	7.04e-05	0.00128	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—NOS2—psoriasis	6.95e-05	0.00127	CbGpPWpGaD
Dapagliflozin—Rash—Prednisone—psoriasis	6.86e-05	0.000416	CcSEcCtD
Dapagliflozin—Dermatitis—Prednisone—psoriasis	6.86e-05	0.000415	CcSEcCtD
Dapagliflozin—Headache—Prednisone—psoriasis	6.82e-05	0.000413	CcSEcCtD
Dapagliflozin—UGT1A9—Metabolism—NDUFA5—psoriasis	6.82e-05	0.00124	CbGpPWpGaD
Dapagliflozin—Hypersensitivity—Methotrexate—psoriasis	6.7e-05	0.000406	CcSEcCtD
Dapagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	6.64e-05	0.00121	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	6.62e-05	0.00121	CbGpPWpGaD
Dapagliflozin—Nausea—Prednisone—psoriasis	6.46e-05	0.000392	CcSEcCtD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	6.36e-05	0.00116	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—APOE—psoriasis	6.25e-05	0.00114	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—CAT—psoriasis	6.09e-05	0.00111	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—CAT—psoriasis	6.09e-05	0.00111	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—HLA-A—psoriasis	6.05e-05	0.0011	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—HLA-A—psoriasis	6.05e-05	0.0011	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—TNF—psoriasis	6.04e-05	0.0011	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	6.04e-05	0.0011	CbGpPWpGaD
Dapagliflozin—Dizziness—Methotrexate—psoriasis	6.01e-05	0.000364	CcSEcCtD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	5.95e-05	0.00108	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—CYP2S1—psoriasis	5.8e-05	0.00106	CbGpPWpGaD
Dapagliflozin—Rash—Methotrexate—psoriasis	5.73e-05	0.000347	CcSEcCtD
Dapagliflozin—Dermatitis—Methotrexate—psoriasis	5.73e-05	0.000347	CcSEcCtD
Dapagliflozin—Headache—Methotrexate—psoriasis	5.7e-05	0.000345	CcSEcCtD
Dapagliflozin—SLC5A4—Disease—TYK2—psoriasis	5.69e-05	0.00104	CbGpPWpGaD
Dapagliflozin—CYP1A1—PPARA activates gene expression—PPARG—psoriasis	5.66e-05	0.00103	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—APOE—psoriasis	5.65e-05	0.00103	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—APOE—psoriasis	5.65e-05	0.00103	CbGpPWpGaD
Dapagliflozin—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	5.54e-05	0.00101	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—PPARG—psoriasis	5.44e-05	0.000992	CbGpPWpGaD
Dapagliflozin—Nausea—Methotrexate—psoriasis	5.4e-05	0.000327	CcSEcCtD
Dapagliflozin—SLC5A1—Disease—NOS2—psoriasis	5.27e-05	0.00096	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—NOS2—psoriasis	5.27e-05	0.00096	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—NDUFA5—psoriasis	5.25e-05	0.000958	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—CD4—psoriasis	5.15e-05	0.000939	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	5.14e-05	0.000937	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	4.95e-05	0.000902	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—IFNG—psoriasis	4.83e-05	0.000881	CbGpPWpGaD
Dapagliflozin—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	4.82e-05	0.00088	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—APOE—psoriasis	4.73e-05	0.000863	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—APOE—psoriasis	4.73e-05	0.000863	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—CAT—psoriasis	4.7e-05	0.000858	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—CXCL8—psoriasis	4.49e-05	0.000819	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	4.49e-05	0.000819	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CYP2S1—psoriasis	4.47e-05	0.000815	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—TYK2—psoriasis	4.31e-05	0.000787	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—TYK2—psoriasis	4.31e-05	0.000787	CbGpPWpGaD
Dapagliflozin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	4.21e-05	0.000768	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—PPARG—psoriasis	4.12e-05	0.000752	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—PPARG—psoriasis	4.12e-05	0.000752	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—STAT3—psoriasis	3.99e-05	0.000727	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—NDUFA5—psoriasis	3.92e-05	0.000714	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—CD4—psoriasis	3.9e-05	0.000711	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—CD4—psoriasis	3.9e-05	0.000711	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	3.85e-05	0.000702	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	3.85e-05	0.000702	CbGpPWpGaD
Dapagliflozin—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	3.82e-05	0.000696	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	3.7e-05	0.000675	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—APOE—psoriasis	3.66e-05	0.000666	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.65e-05	0.000666	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—VEGFA—psoriasis	3.65e-05	0.000665	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—CARM1—psoriasis	3.48e-05	0.000635	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CYP2S1—psoriasis	3.33e-05	0.000607	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—PPARG—psoriasis	3.18e-05	0.00058	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—TNF—psoriasis	3.13e-05	0.00057	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—NDUFA5—psoriasis	3.13e-05	0.00057	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	3.11e-05	0.000567	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.04e-05	0.000554	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—STAT3—psoriasis	3.02e-05	0.000551	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—STAT3—psoriasis	3.02e-05	0.000551	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—NDUFA5—psoriasis	2.95e-05	0.000537	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NDUFA5—psoriasis	2.92e-05	0.000533	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	2.91e-05	0.00053	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—CARM1—psoriasis	2.83e-05	0.000516	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—IL6—psoriasis	2.78e-05	0.000508	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	2.77e-05	0.000505	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.72e-05	0.000497	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP2S1—psoriasis	2.66e-05	0.000485	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.65e-05	0.000482	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP2S1—psoriasis	2.51e-05	0.000457	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NDUFA5—psoriasis	2.5e-05	0.000455	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP2S1—psoriasis	2.48e-05	0.000453	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.33e-05	0.000424	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CARM1—psoriasis	2.18e-05	0.000398	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—CAT—psoriasis	2.14e-05	0.000391	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP2S1—psoriasis	2.12e-05	0.000387	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—IL6—psoriasis	2.11e-05	0.000385	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—IL6—psoriasis	2.11e-05	0.000385	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.06e-05	0.000376	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.98e-05	0.000362	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NDUFA5—psoriasis	1.93e-05	0.000351	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.8e-05	0.000328	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.74e-05	0.000318	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—CAT—psoriasis	1.74e-05	0.000317	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—APOE—psoriasis	1.66e-05	0.000304	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP2S1—psoriasis	1.64e-05	0.000299	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CARM1—psoriasis	1.63e-05	0.000296	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.54e-05	0.000281	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.52e-05	0.000277	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PPARG—psoriasis	1.45e-05	0.000264	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.36e-05	0.000248	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—APOE—psoriasis	1.35e-05	0.000247	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CAT—psoriasis	1.34e-05	0.000245	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.3e-05	0.000237	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CARM1—psoriasis	1.3e-05	0.000237	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CARM1—psoriasis	1.22e-05	0.000223	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CARM1—psoriasis	1.21e-05	0.000221	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PPARG—psoriasis	1.18e-05	0.000215	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.13e-05	0.000207	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.11e-05	0.000203	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—APOE—psoriasis	1.04e-05	0.00019	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CARM1—psoriasis	1.04e-05	0.000189	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CAT—psoriasis	1e-05	0.000182	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.69e-06	0.000177	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PPARG—psoriasis	9.08e-06	0.000166	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CARM1—psoriasis	8e-06	0.000146	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CAT—psoriasis	7.99e-06	0.000146	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—APOE—psoriasis	7.77e-06	0.000142	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CAT—psoriasis	7.53e-06	0.000137	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CAT—psoriasis	7.46e-06	0.000136	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PPARG—psoriasis	6.77e-06	0.000123	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CAT—psoriasis	6.38e-06	0.000116	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—APOE—psoriasis	6.21e-06	0.000113	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—APOE—psoriasis	5.85e-06	0.000107	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—APOE—psoriasis	5.8e-06	0.000106	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PPARG—psoriasis	5.41e-06	9.86e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PPARG—psoriasis	5.09e-06	9.29e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PPARG—psoriasis	5.05e-06	9.21e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—APOE—psoriasis	4.95e-06	9.03e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CAT—psoriasis	4.92e-06	8.97e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PPARG—psoriasis	4.32e-06	7.87e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—APOE—psoriasis	3.82e-06	6.97e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PPARG—psoriasis	3.33e-06	6.07e-05	CbGpPWpGaD
